Nuclear TAZ expression associates with the triple-negative phenotype in breast cancer

Endocrine-Related Cancer

Volumn 22, Issue 3, 2015, Pages 443-454

  Díaz Martín, Juan ^a,b   López García, María Ángeles ^a   Romero Pérez, Laura ^a   Atienza Amores, María Reina ^a   Pecero, María Luisa ^a   Castilla, María Ángeles ^a   Biscuola, Michele ^a   Santón, Almudena ^c   Palacios, José ^c  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b Red Tematica de Investigacion Cooperativa en Cancer   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Epithelial mesenchymal transition; Hippo signaling; TAZ oncoprotein; Triple negative breast cancer

Indexed keywords

ONCOPROTEIN; TAZ ONCOPROTEIN; TRANSCRIPTION FACTOR YAP1; UNCLASSIFIED DRUG; TAZ PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER CELL LINE; BREAST CARCINOMA; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA METHYLATION; EPITHELIAL MESENCHYMAL TRANSITION; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MIDDLE AGED; OVERALL SURVIVAL; PROGESTERONE RECEPTOR POSITIVE BREAST CANCER; PROMOTER REGION; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TISSUE MICROARRAY; TRIPLE NEGATIVE BREAST CANCER; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; METABOLISM; PATHOLOGY; PHENOTYPE; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TUMOR CELL LINE;

BIOMARKERS, TUMOR; CELL LINE, TUMOR; DNA METHYLATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; PHENOTYPE; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TRANSCRIPTION FACTORS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84937045948     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-14-0456     Document Type: Article

References (35)

1. Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR et al. 2011 Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Modern Pathology 24 157-167. (doi:10.1038/modpathol.2010.200)
2. Bartucci M, Dattilo R, Moriconi C, Pagliuca A, Mottolese M, Federici G, Benedetto AD, Todaro M, Stassi G, Sperati F et al. 2014 TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells. Oncogene 34 681-690. (doi:10.1038/onc.2014.5)
3. Bayraktar S & Gluck S 2013 Molecularly targeted therapies for metastatic triple-negative breast cancer. Breast Cancer Research and Treatment 138 21-35. (doi:10.1007/s10549-013-2421-5)
4. Bertucci F, Finetti P, Cervera N, Esterni B, Hermitte F, Viens P& Birnbaum D 2008 How basal are triple-negative breast cancers? International Journal of Cancer 123 236-240. (doi:10.1002/ijc.23518)
5. Bhat KP, Salazar KL, Balasubramaniyan V, Wani K, Heathcock L, Hollingsworth F, James JD, Gumin J, Diefes KL, Kim SH et al. 2011 The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes and Development 25 2594-2609. (doi:10.1101/gad.176800.111)
6. Castilla MA, Diaz-Martin J, Sarrio D, Romero-Perez L, Lopez-Garcia MA, Vieites B, Biscuola M, Ramiro-Fuentes S, Isacke CM & Palacios J 2012 MicroRNA-200 family modulation in distinct breast cancer phenotypes. PLoS ONE 7 e47709. (doi:10.1371/journal.pone.0047709)
7. Castilla MA, Lopez-Garcia MA, Atienza MR, Rosa-Rosa JM, Diaz-Martin J, Pecero ML, Vieites B, Romero-Perez L, Benitez J, Calcabrini A et al. 2014 VGLL1 expression is associated with a triple-negative basal-like phenotype in breast cancer. Endocrine-Related Cancer 21 587-599. (doi:10.1530/ERC-13-0485)
8. Chan SW, Lim CJ, Guo K, Ng CP, Lee I, Hunziker W, Zeng Q & Hong W 2008 A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Research 68 2592-2598. (doi:10.1158/0008-5472.CAN-07-2696)
9. Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, Frasson C, Inui M, Montagner M, Parenti AR, Poletti A et al. 2011 The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 147 759-772. (doi:10.1016/j.cell.2011.09.048)
10. de Cristofaro T, Di Palma T, Ferraro A, Corrado A, Lucci V, Franco R, Fusco A & Zannini M 2011 TAZ/WWTR1 is overexpressed in papillary thyroid carcinoma. European Journal of Cancer 47 926-933. (doi:10.1016/j.ejca.2010.11.008)
11. Ding L, Ellis MJ, Li S, Larson DE, ChenK,Wallis JW, Harris CC, McLellanMD, Fulton RS, Fulton LL et al. 2010 Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464 999-1005. (doi:10.1038/nature08989)
12. Duffy MJ, McGowan PM & Crown J 2012 Targeted therapy for triplenegative breast cancer: where are we? International Journal of Cancer 131 2471-2477. (doi:10.1002/ijc.27632)
13. Foulkes WD, Smith IE & Reis-Filho JS 2010 Triple-negative breast cancer. New England Journal of Medicine 363 1938-1948. (doi:10.1056/NEJMra1001389)
14. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B & Senn HJ 2011 Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Annals of Oncology 22 1736-1747. (doi:10.1093/annonc/mdr304)
15. Harvey KF, Zhang X & Thomas DM 2013 The Hippo pathway and human cancer. Nature Reviews. Cancer 13 246-257. (doi:10.1038/nrc3458)
16. Hiemer SE, Szymaniak AD & Varelas X 2014 The transcriptional regulators TAZ and YAP direct transforming growth factor b-induced tumorigenic phenotypes in breast cancer cells. Journal of Biological Chemistry 289 13461-13474. (doi:10.1074/jbc.M113.529115)
17. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y & Pietenpol JA 2011 Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. Journal of Clinical Investigation 121 2750-2767. (doi:10.1172/JCI45014)
18. Moreno-Bueno G, Peinado H, Molina P, Olmeda D, Cubillo E, Santos V, Palacios J, Portillo F & Cano A 2009 The morphological and molecular features of the epithelial-to-mesenchymal transition. Nature Protocols 4 1591-1613. (doi:10.1038/nprot.2009.152)
19. Pan D 2010 The hippo signaling pathway in development and cancer. Developmental Cell 19 491-505. (doi:10.1016/j.devcel.2010.09.011)
20. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z et al. 2009 Supervised risk predictor of breast cancer based on intrinsic subtypes. Journal of Clinical Oncology 27 1160-1167. (doi:10.1200/JCO.2008.18.1370)
21. Piccolo S & Cordenonsi M 2013 Regulation of YAP and TAZ by epithelial plasticity. In The Hippo Signaling Pathway and Cancer, pp 89-113. Eds M Oren & Y Aylon. New York, NY: Springer. (doi:10.1007/978-1-4614-6220-0-6)
22. Prat A, Adamo B, Cheang MC, Anders CK, Carey LA & Perou CM 2013 Molecular characterization of basal-like and non-basal-like triplenegative breast cancer. Oncologist 18 123-133. (doi:10.1634/theoncologist.2012-0397)
23. Reinhold WC, Sunshine M, Liu H, Varma S, Kohn KW, Morris J, Doroshow J & Pommier Y 2012 CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Research 72 3499-3511. (doi:10.1158/0008-5472.CAN-12-1370)
24. Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G & Palacios J 2008 Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Research 68 989-997. (doi:10.1158/0008-5472.CAN-07-2017)
25. Serrano I, McDonald PC, Lock F, MullerWJ & Dedhar S 2013 Inactivation of the Hippo tumour suppressor pathway by integrin-linked kinase. Nature Communications 4 2976. (doi:10.1038/ncomms3976)
26. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, Haffari G et al. 2012 The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486 395-399. (doi:10.1038/nature10933)
27. Skibinski A, Breindel JL, Prat A, Galvan P, Smith E, Rolfs A, Gupta PB, Labaer J & Kuperwasser C 2014 The Hippo transducer TAZ interacts with the SWI/SNF complex to regulate breast epithelial lineage commitment. Cell Reports 6 1059-1072. (doi:10.1016/j.celrep.2014.02.038)
28. Steinhardt AA,Gayyed MF, Klein AP, Dong J,Maitra A, Pan D, Montgomery EA & Anders RA 2008 Expression of yes-associated protein in common solid tumors. Human Pathology 39 1582-1589. (doi:10.1016/j.humpath.2008.04.012)
29. TCGA 2012 Comprehensive molecular portraits of human breast tumours. Nature 490 61-70. (doi:10.1038/nature11412)
30. Toft DJ & Cryns VL 2011 Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies. Molecular Endocrinology 25 199-211. (doi:10.1210/me.2010-0164)
31. Varelas X & Wrana JL 2012 Coordinating developmental signaling: novel roles for the Hippo pathway. Trends in Cell Biology 22 88-96. (doi:10.1016/j.tcb.2011.10.002)
32. Wang L, Shi S, Guo Z, Zhang X, Han S, Yang A, Wen W & Zhu Q 2013 Overexpression of YAP and TAZ is an independent predictor of prognosis in colorectal cancer and related to the proliferation and metastasis of colon cancer cells. PLoS ONE 8 e65539. (doi:10.1371/journal.pone.0065539)
33. Xie M, Zhang L, He CS, Hou JH, Lin SX, Hu ZH, Xu F & Zhao HY 2012 Prognostic significance of TAZ expression in resected non-small cell lung cancer. Journal of Thoracic Oncology 7 799-807. (doi:10.1097/JTO.0b013e318248240b)
34. Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, Fan ST, Luk JM, Wigler M, Hannon GJ et al. 2006 Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 125 1253-1267. (doi:10.1016/j.cell.2006.05.030)
35. Zhao B, Tumaneng K & Guan KL 2011 The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nature Cell Biology 13 877-883. (doi:10.1038/ncb2303)